VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Viridian Therapeutics, Inc. (VRDN) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Value (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C- (2.1) | B- (2.9) | C (2.2) | B (3.3) | C+ (2.6) | C+ (2.6) |
| 2026-11-08 | C (2.3) | B- (2.9) | C (2.2) | B (3.2) | C+ (2.6) | C+ (2.6) |
| 2026-11-01 | C+ (2.8) | A- (3.9) | C (2.3) | B+ (3.6) | C+ (2.7) | B- (3.1) |
| 2026-10-25 | C+ (2.8) | A- (3.9) | C (2.3) | B (3.5) | C+ (2.6) | B- (3.0) |
| 2026-10-18 | C+ (2.8) | A- (3.9) | C (2.3) | B (3.4) | C+ (2.6) | B- (3.0) |